Brief: Corvus Pharmaceuticals Announces Data From Cohort 2 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
13/01/2025 13:44
Jan 13 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS ANNOUNCES DATA FROM COHORT 2 OF
PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR
ATOPIC DERMATITIS
* COHORT 2 FULLY ENROLLED, FULL RESULTS EXPECTED IN Q2 2025
* DATA SHOW FAVORABLE SAFETY AND EFFICACY PROFILE
Source text: ID:nGNX8y27jQ
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental